The GLP-1 Market in 2025: Why Retatrutide Changes Everything

The GLP-1 market has been the defining story in healthcare for the past three years. Semaglutide (Ozempic, Wegovy) created a category. Tirzepatide (Mounjaro, Zepbound) expanded it. Now Retatrutide — the triple agonist — is positioned to redefine it again.

For telehealth operators, understanding where this market is heading isn't optional. It's the difference between building a business that captures the next wave and one that's still riding the last one.

GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone, which regulates blood sugar and appetite. The original GLP-1 medications were developed for Type 2 diabetes. The weight loss applications emerged as a secondary finding — and then became the primary market.

Semaglutide's clinical trials showed average weight loss of 15-17% of body weight. That was unprecedented for a pharmaceutical intervention. The demand was immediate and enormous.

Tirzepatide added a second mechanism — GIP receptor agonism — creating a dual agonist that showed even stronger results in clinical trials. Average weight loss in the SURMOUNT trials exceeded 20% of body weight.

Both medications became available as compounded versions through 503A and 503B pharmacies, which is what enabled the telehealth weight management market to scale the way it did.

Retatrutide is a triple agonist — it targets GLP-1, GIP, and glucagon receptors simultaneously. The clinical data from Phase 2 trials was striking: average weight loss of approximately 24% of body weight over 48 weeks.

That's not an incremental improvement. That's a step change in efficacy.

The mechanism matters for operators to understand. The glucagon receptor component increases energy expenditure — not just appetite suppression. Patients lose weight through a combination of eating less and burning more. The clinical profile is meaningfully different from the dual agonists.

Retatrutide is not yet FDA-approved as a branded medication. That means it's available through compounding pharmacies — the same pathway that made Semaglutide and Tirzepatide accessible to the telehealth market.

For operators who are already running GLP-1 programs, adding Retatrutide to your formulary is a natural extension. For operators who are building new brands, Retatrutide is a differentiated product that your competitors may not yet be offering.

The window for first-mover advantage in new compounds is real. Operators who were early to Tirzepatide built patient bases and brand recognition that their later-moving competitors are still trying to catch.

Running a Retatrutide program requires the same infrastructure as any GLP-1 program — plus a few additional considerations.

Clinical protocols. Retatrutide's triple mechanism means the clinical protocols need to reflect its specific profile. Dosing, titration schedules, and monitoring requirements differ from Semaglutide and Tirzepatide. Your protocols need to be written and reviewed by clinicians who understand the compound.

Provider training. Your prescribing providers need to understand Retatrutide's mechanism, its clinical data, and its contraindications. This isn't a drop-in replacement for existing GLP-1 protocols.

Patient education. Patients who have been on Semaglutide or Tirzepatide will have questions about how Retatrutide differs. Your intake and patient communication materials need to address this.

Pharmacy sourcing. Not every compounding pharmacy in your network will have Retatrutide available. Confirm availability and quality standards before you launch a program.

The GLP-1 market is not a trend. It's a structural shift in how obesity and metabolic disease are treated. The pipeline of next-generation compounds is deep — oral formulations, longer-acting injectables, combination therapies.

Operators who build their businesses on solid infrastructure — compliant protocols, quality pharmacy networks, scalable operations — are positioned to capture each new wave as it arrives. Operators who built on shortcuts will find themselves unable to adapt.

The brands that will be acquired for $10M+ in the next three to five years are the ones being built right now, on infrastructure that can scale and evolve.

Retatrutide represents a genuine opportunity for telehealth operators. The clinical data is compelling, the compounding pathway is available, and patient demand for more effective weight management solutions is not going away.

The operators who move early, build the right protocols, and source from quality pharmacies will have a meaningful advantage. The window is open now.

TeleMed Shop's product catalog includes Retatrutide alongside Semaglutide, Tirzepatide, and the full range of GLP-1 compounds. Our 50-state pharmacy network ensures availability regardless of where your patients are located.